These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 11426843

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide.
    Osei-Hyiaman D, Depetrillo M, Harvey-White J, Bannon AW, Cravatt BF, Kuhar MJ, Mackie K, Palkovits M, Kunos G.
    Neuroendocrinology; 2005; 81(4):273-82. PubMed ID: 16131814
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors.
    Gatley SJ, Gifford AN, Volkow ND, Lan R, Makriyannis A.
    Eur J Pharmacol; 1996 Jul 04; 307(3):331-8. PubMed ID: 8836622
    [Abstract] [Full Text] [Related]

  • 29. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
    Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, Shohami E, Spatz M.
    Brain Res Mol Brain Res; 2004 Dec 06; 132(1):87-92. PubMed ID: 15548432
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
    Derocq JM, Bouaboula M, Marchand J, Rinaldi-Carmona M, Ségui M, Casellas P.
    FEBS Lett; 1998 Apr 03; 425(3):419-25. PubMed ID: 9563506
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
    Welch SP, Huffman JW, Lowe J.
    J Pharmacol Exp Ther; 1998 Sep 03; 286(3):1301-8. PubMed ID: 9732392
    [Abstract] [Full Text] [Related]

  • 37. Comparisons of Δ9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates.
    Kangas BD, Leonard MZ, Shukla VG, Alapafuja SO, Nikas SP, Makriyannis A, Bergman J.
    J Pharmacol Exp Ther; 2016 Apr 03; 357(1):125-33. PubMed ID: 26826191
    [Abstract] [Full Text] [Related]

  • 38. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
    Després JP.
    Crit Pathw Cardiol; 2007 Jun 03; 6(2):46-50. PubMed ID: 17667864
    [Abstract] [Full Text] [Related]

  • 39. Acute effects of endocannabinoid anandamide and CB1 receptor antagonist, AM251 in the regulation of thyrotropin secretion.
    da Veiga MA, Fonseca Bloise F, Costa-E-Sousa RH, Souza LL, Almeida NA, Oliveira KJ, Pazos-Moura CC.
    J Endocrinol; 2008 Nov 03; 199(2):235-42. PubMed ID: 18755884
    [Abstract] [Full Text] [Related]

  • 40. Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits.
    Pate DW, Järvinen K, Urtti A, Mahadevan V, Järvinen T.
    Life Sci; 1998 Nov 03; 63(24):2181-8. PubMed ID: 9851310
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.